Original ArticlesUse of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non-small Cell Lung Cancer
Under an Elsevier user license
open archive
Key Words:
Non-small cell lung cancer
miR-7
miR-221
miR-155
miR-21
let7a
miR-210
MicroRNA
Recurrence
Prognosis
Stage I
Cited by (0)
Disclosure: Ramaswamy Govindan, MD, has served as an advisor for Genentech, Lilly Oncology, AstraZeneca, GSK, and Boehringer Ingelheim. The other authors declare no conflicts of interest.
Drs. Duncavage and Goodgame contributed equally to this manuscript.
Copyright © 2010 International Association for the Study of Lung Cancer. All rights reserved.